WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$5.68 USD
-0.26 (-4.38%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.69 +0.01 (0.18%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
WVE 5.68 -0.26(-4.38%)
Will WVE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for WVE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WVE
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
WVE: What are Zacks experts saying now?
Zacks Private Portfolio Services
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?
Other News for WVE
Commit To Purchase Wave Life Sciences At $5, Earn 34.9% Annualized Using Options
Wave Life Sciences initiated with bullish view at B. Riley, here's why
Wave Life Sciences gains as B. Riley issues buy on RNS editing tech
Wave Life Sciences: A Buy Rating on Groundbreaking RNA Therapies and Promising Clinical Trials
Wave Life Sciences initiated with bullish view at B. Riley